Twist Bioscience CorporationTWSTNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank44
3Y CAGR-50.2%
5Y CAGR-49.3%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-50.2%/yr
vs -28.6%/yr prior
5Y CAGR
-49.3%/yr
Consistent
Acceleration
-21.6pp
Decelerating
Percentile
P44
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 0.68% |
| Q3 2025 | -5.72% |
| Q2 2025 | -24.54% |
| Q1 2025 | 12.25% |
| Q4 2024 | 0.82% |
| Q3 2024 | -5.94% |
| Q2 2024 | -6.96% |
| Q1 2024 | 4.55% |
| Q4 2023 | -2.72% |
| Q3 2023 | -3.19% |
| Q2 2023 | -10.41% |
| Q1 2023 | -12.36% |
| Q4 2022 | 5.53% |
| Q3 2022 | -19.64% |
| Q2 2022 | 17.96% |
| Q1 2022 | 38.01% |
| Q4 2021 | 16.39% |
| Q3 2021 | -1.99% |
| Q2 2021 | 25.63% |
| Q1 2021 | 12.79% |
| Q4 2020 | 20.32% |
| Q3 2020 | 11.41% |
| Q2 2020 | -1.74% |
| Q1 2020 | 3.22% |
| Q4 2019 | -1.90% |
| Q3 2019 | 16.53% |
| Q2 2019 | 1.12% |
| Q1 2019 | 22.47% |
| Q4 2018 | 19.92% |
| Q3 2018 | 15.13% |
| Q2 2018 | 11.82% |
| Q1 2018 | 9.48% |
| Q4 2017 | -11.30% |
| Q3 2017 | -8.07% |
| Q2 2017 | 0.00% |